6.0 KiB
| title | chunk | source | category | tags | date_saved | instance |
|---|---|---|---|---|---|---|
| Asymmetric hydrogenation | 1/4 | https://en.wikipedia.org/wiki/Asymmetric_hydrogenation | reference | science, encyclopedia | 2026-05-05T10:46:00.770091+00:00 | kb-cron |
Asymmetric hydrogenation is a chemical reaction that adds two atoms of hydrogen to a target (substrate) molecule with three-dimensional spatial selectivity. Critically, this selectivity does not come from the target molecule itself, but from other reagents or catalysts present in the reaction. This allows spatial information (what chemists refer to as chirality) to transfer from one molecule to the target, forming the product as a single enantiomer. The chiral information is most commonly contained in a catalyst and, in this case, the information in a single molecule of catalyst may be transferred to many substrate molecules, amplifying the amount of chiral information present. Similar processes occur in nature, where a chiral molecule like an enzyme can catalyse the introduction of a chiral centre to give a product as a single enantiomer, such as amino acids, that a cell needs to function. By imitating this process, chemists can generate many novel synthetic molecules that interact with biological systems in specific ways, leading to new pharmaceutical agents and agrochemicals. The importance of asymmetric hydrogenation in both academia and industry contributed to two of its pioneers — William Standish Knowles and Ryōji Noyori — being collectively awarded one half of the 2001 Nobel Prize in Chemistry.
== History ==
In 1956 a heterogeneous catalyst made of palladium deposited on silk was shown to effect asymmetric hydrogenation. Later, in 1968, the groups of William Knowles and Leopold Horner independently published the examples of asymmetric hydrogenation using a homogeneous catalysts. While exhibiting only modest enantiomeric excesses, these early reactions demonstrated feasibility. By 1972, enantiomeric excess of 90% was achieved, and the first industrial synthesis of the Parkinson's drug L-DOPA commenced using this technology.
The field of asymmetric hydrogenation continued to experience a number of notable advances. Henri Kagan developed DIOP, an easily prepared C2-symmetric diphosphine that gave high ee's in certain reactions. Ryōji Noyori and co-workers introduced ruthenium–BINAP catalysts for the asymmetric hydrogenation of polar substrates, including functionalized ketones. Robert H. Crabtree demonstrated the ability for Iridium compounds to catalyse asymmetric hydrogenation reactions in 1979 with the invention of Crabtree's catalyst. In the early 1990's, the introduction of P,N ligands by several groups independently then further expanded the scope of the C2-symmetric ligands, although they are not fundamentally superior to chiral ligands lacking rotational symmetry.
Today, asymmetric hydrogenation is a routine methodology in laboratory and industrial scale organic chemistry. The importance of asymmetric hydrogenation was recognized by the 2001 Nobel Prize in Chemistry awarded to William Standish Knowles and Ryōji Noyori.
== Mechanism == Asymmetric hydrogenations operate by conventional mechanisms invoked for other hydrogenations. This includes inner sphere mechanisms, outer sphere mechanisms and the σ-bond metathesis mechanisms. The type of mechanism employed by a catalyst is largely dependent on the ligands used in a system, which in turn leads to certain catalyst-substrate affinities.
=== Inner sphere mechanisms === The so-called inner sphere mechanism entails coordination of the alkene to the metal center. Other characteristics of this mechanism include a tendency for a homolytic splitting of dihydrogen when more electron-rich, low-valent metals are present while electron-poor, high valent metals normally exhibit a heterolytic cleavage of dihydrogen assisted by a base. The diagram below depicts purposed mechanisms for catalytic hydrogenation with rhodium complexes which are inner sphere mechanisms. In the unsaturated mechanism, the chiral product formed will have the opposite mode compared to the catalyst used. While the thermodynamically favoured complex between the catalyst and the substrate is unable to undergo hydrogenation, the unstable, unfavoured complex undergoes hydrogenation rapidly. The dihydride mechanism on the other hand sees the complex initially hydrogenated to the dihydride form. This subsequently allows for the coordination of the double bond on the non-hindered side. Through insertion and reductive elimination, the product's chirality matches that of the ligand.
The preference for producing one enantiomer instead of another in these reactions is often explained in terms of steric interactions between the ligand and the prochiral substrate. Consideration of these interactions has led to the development of quadrant diagrams where "blocked" areas are denoted with a shaded box, while "open" areas are left unfilled. In the modeled reaction, large groups on an incoming olefin will tend to orient to fill the open areas of the diagram, while smaller groups will be directed to the blocked areas and hydrogen delivery will then occur to the back face of the olefin, fixing the stereochemistry. Note that only part of the chiral phosphine ligand is shown for the sake of clarity.
=== Outer sphere mechanisms === Some catalysts operate by "outer sphere mechanisms" such that the substrate never bonds directly to the metal but rather interacts with its ligands, which is often a metal hydride and a protic hydrogen on a ligand. As such, in most cases dihydrogen is split heterolytically, with the metal acting as a Lewis acid and either an external or internal base "deprotonating" the hydride.
For an example of this mechanism we can consider the BINAP-Ru-diamine system. The dihalide form of the catalyst is converted to the catalysts by reaction of H2 in the presence of base:
RuCl2(BINAP)(diamine) + 2 KOBu-t + 2 H2 → RuH2(BINAP)(diamine) + 2 KCl + 2 HOBu-t The resulting catalysts have three kinds of ligands: